mTOR

mTOR, short for mechanistic target of rapamycin, is an enzyme inside almost every cell that reads how much food, energy and growth signal is available and decides whether the cell should build or repair. When nutrients are plentiful, mTOR drives growth: making protein, storing fat, dividing. When they are scarce, it stands down and lets the cell clean house instead. It is named after the drug that blocks it, rapamycin, isolated from a soil bacterium collected on Rapa Nui (Easter Island). The reference entry on mTOR works through the same pathway in more detail.

What it measures

mTOR is a kinase — a protein that switches other proteins on and off by attaching a phosphate group — so it is a control point, not a number on a lab report. It operates inside two different assemblies. mTORC1 is the one most of the longevity discussion is about: it senses amino acids, leucine above all, along with insulin, IGF-1 and the cell’s energy status, and it is the complex rapamycin blocks directly. mTORC2 sits in a separate arm handling insulin signaling and cell architecture, and is disturbed only by prolonged exposure.

Downstream, active mTORC1 turns on the machinery that translates messenger RNA into new protein and turns off Autophagy, the recycling program a cell runs when food is short. Researchers estimate its activity indirectly, by measuring how heavily its target proteins are phosphorylated in cells or in a tissue biopsy. There is no blood test or consumer panel that tells you your mTOR level.

Why it matters for longevity

Nutrient sensing is one of the hallmarks of aging, and mTOR is its central node. Turning the pathway down, genetically or with a drug, extends lifespan in yeast, worms, flies and mice — one of the few interventions that keeps working across very distant species. Rapamycin raised median lifespan in mice in the National Institute on Aging’s Interventions Testing Program even when dosing began in mid to late life, the most reproducible drug result the field has. The proposed reason is that constant growth signaling leaves damaged proteins uncleared, while easing off restores autophagy and slows the accumulation.

Human evidence stops well short of that. No trial has shown that inhibiting mTOR extends life or slows aging in people. Small trials of rapamycin analogs improved older adults’ antibody response to influenza vaccination, and a trial of low intermittent doses in healthy adults found them broadly tolerated with modest effects. At transplant doses rapamycin suppresses the immune system and can cause mouth ulcers, poor wound healing and changes in blood lipids and glucose. mTOR is also not a villain to be switched off: you need it to build muscle, heal wounds and mount an immune response. The open question is dose and timing, not elimination.

What changes it

Food is the main lever. Calories and dietary protein — particularly the amino acid leucine — activate mTORC1 within a couple of hours of a meal, and a long gap without eating lets it fall back. Insulin and IGF-1 raise it, which is part of why chronic overeating is described as a pro-growth state. Pulling the other way is AMPK, the sensor that responds to low cellular energy and restrains mTORC1; exercise and metformin both act on that side of the seesaw.

Training complicates the simple story in a useful way. Resistance exercise raises mTORC1 activity in the muscle you just worked, for hours afterwards, and that is precisely what should happen there — it is how muscle protein is built. Endurance work and fasting push the pathway down. So the honest advice is not “suppress mTOR”: eat enough protein to hold your muscle, train, and avoid a permanent calorie surplus. Rapamycin itself is a prescription immunosuppressant; its off-label use for aging rests on animal data, not on human outcomes.

Related reading

Disclaimer. This article is for information only and does not replace medical advice. Talk to a qualified clinician before changing anything about your health.